Dr. Keith Keer on PD-L1 in Lung Cancer

Keith Kerr, BSc, MB ChB
Published: Wednesday, May 25, 2016



Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.
 
Right now the only biomarker with validated data in lung cancer is PD-L1 immunohistochemistry. It is perceived as not being a good biomarker, but it is unfairly judged says Kerr.
 
It often gets compared to EGFR mutation or ALK translocation which are very effective biomarkers, but PD-L1 is not the only controlling factor within the immune response and it will never have the level of predictive power as those biomarkers. Expectations of PD-L1 need to be downgraded, says Kerr.
 
However, it can be improved. Right now each PD-L1 inhibitor has its own immunohistochemistry test and they are not all the same. It is not practical to do multiple test, so there needs to be simplification, says Keer.
 


Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.
 
Right now the only biomarker with validated data in lung cancer is PD-L1 immunohistochemistry. It is perceived as not being a good biomarker, but it is unfairly judged says Kerr.
 
It often gets compared to EGFR mutation or ALK translocation which are very effective biomarkers, but PD-L1 is not the only controlling factor within the immune response and it will never have the level of predictive power as those biomarkers. Expectations of PD-L1 need to be downgraded, says Kerr.
 
However, it can be improved. Right now each PD-L1 inhibitor has its own immunohistochemistry test and they are not all the same. It is not practical to do multiple test, so there needs to be simplification, says Keer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x